Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deltex Injunction Demonstrates Need For Fast Response To FDA Inspections

This article was originally published in The Tan Sheet

Executive Summary

An injunction prohibiting Deltex Pharmaceuticals from making drugs until it complies with good manufacturing practices and other regulations reminds firms that "the leash may not be as long" under the current FDA as in the past, a health care attorney says.

You may also be interested in...

FDA Issues More Warning Letters, Drops Follow-Up Letters In Favor Of Action

FDA will warn firms only once - if at all - before taking stronger enforcement actions to stop systematic quality and safety problems, said Howard Sklamberg, director of the Office of Enforcement at the Office of Regulatory Affairs

One-Third Of Supplement GMP Inspections Reveal "Serious Problems" - FDA

About one-third of the 90 dietary supplement good manufacturing practices inspections FDA completed in fiscal 2010 by the start of September revealed serious compliance problems, according to Principal Deputy Commissioner Josh Sharfstein

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts